Richard Boyce
ABSTRACT
Multiple studies indicate that drug-drug interactions are a significant source of preventable adverse drug events. Factors contributing to the occurrence of preventable ADEs resulting from DDIs include a lack of knowledge of the patient's concurrent medications and inaccurate or inadequate knowledge of interactions by health care providers. FDA-approved drug product labeling is a major source of information intended to help clinicians prescribe drugs in a safe and effective manner. Unfortunately, drug product labeling has been identified as often lagging behind emerging drug knowledge; especially when it has been several years since a drug has been released to the market. In this paper we report on a novel approach that explores employing Semantic Web technology and natural language processing to identify drug mechanism information that may update or expand upon statements present in product labeling.
- Amgen. SENSIPAR (cinacalcet hydrochloride) tablet, coated. FDA-approved drug product labeling, 122008. Last accessed on DailyMed 06/29/2009.Google Scholar
- Apotex. fluconazole (fluconazole) solution. FDA-approved drug product labeling, 01 2007. Lastaccessed on DailyMed 05/22/2010.Google Scholar
- R. Boyce, C. Collins, J. Horn, and I. Kalet. Modelingdrug mechanism knowledge using evidence and truth maintenance. IEEE Transactions on Information Technology in Biomedicine, 11(4):386--397, 2007. Google ScholarDigital Library
- R. Boyce, C. Collins, J. Horn, and I. Kalet. Computing with evidence part I: A drug-mechanism evidence taxonomy oriented toward confidence assignment. J Biomed Inform, 42(6):979--989, 2009. Google ScholarDigital Library
- R. Boyce, C. Collins, J. Horn, and I. Kalet. Computing with evidence part II: An evidential approach to predicting metabolic drug-drug interactions. J Biomed Inform, 42(6):990--1003, 2009. Google ScholarDigital Library
- W. W. Chapman, W. Bridewell, P. Hanbury, G. F.Cooper, and B. G. Buchanan. A simple algorithm for identifying negated findings and diseases in discharge summaries. J Biomed Inform, 34(5):301--10, Oct 2001.Google ScholarCross Ref
- Y.-F. Chen, A. Avery, K. Neil, C. Johnson, M. Dewey, and I. Stockly. Incidence and possible causes of prescribing potential hazardous/contraindicated drug combinations in general practice. Drug Safety, 28:67--80, 2005.Google ScholarCross Ref
- Committee on Identifying and Preventing Medication Errors. Preventing medication errors. Technical report, Institute of Medicine, 2006. 0309102685.Google Scholar
- U. Congress. Code of Federal Regulations 21 Part 201, chapter Labeling. Washington, DC: US Government Printing Office, 2010.Google Scholar
- U. Congress. Code of Federal Regulations 21 Part 201.56, chapter Requirements on content and format of labeling for human prescription drug and biological products. Washington, DC: US Government Printing Office, 2010.Google Scholar
- T. Fayruzov, M. D. Cock, C. Cornelis, and V. Hoste. Linguistic feature analysis for protein interaction extraction. BMC Bioinformatics, 10: 374, 2009. PMID: 19909518.Google ScholarCross Ref
- G.D.-Searle-LLC. COVERA-HS (verapamil hydrochloride) tablet, extended release. FDA-approved drug product labeling, 04 2010. Lastaccessed on Daily Med 05/22/2010.Google Scholar
- Global-Pharmaceuticals. GEMFIBROZIL tablet, coated. FDA-approved drug product labeling, 092009. Last accessed on DailyMed 05/22/2010.Google Scholar
- J. Gurwitz, T. Field, J. Judge, P. Rochon, L. Harrold, C. Cadoret, M. Lee, K. White, J. LaPrino, J. Erramuspe-Mainard, M. DeFlorio, L. Gavendo, J. Auger, and D. Bates. The incidence of adverse drug events in two large academic long-term facilities. Am J Med, 118: 251--258, 2005.Google ScholarCross Ref
- Internal. FDA guideline: Drug interaction studies - study design, data analysis, and implications for dosing and labeling. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101. pdf, Sept. 2006. Last Accessed: 03/31/2010.Google Scholar
- IVAX. cimetidine (Cimetidine) tablet, film coated. FDA-approved drug product labeling, 08 2008. Last accessed on DailyMed 12/28/2009.Google Scholar
- D. N. Juurlink, M. Mamdani, A. Kopp, A. Laupacis, and D. A. Redelmeier. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA, 289(13): 1652--1658, 2003.Google ScholarCross Ref
- P. Marroum and J. Gobburu. The product label: how pharmacokinetics and pharmacodynamics reach the prescriber. Clin Pharmacokinet., 41(3):161--9, 2002.Google ScholarCross Ref
- G. Móra, R. Farkas, G. Szarvas, and Z. Molnár. Exploring ways beyond the simple supervised learning approach for biological event extraction. In BioNLP '09: Proceedings of the Workshop on BioNLP, pages 137--140, Morristown, NJ, USA, 2009. Association for Computational Linguistics. Google ScholarDigital Library
- Mutual. PROPAFENONE HYDROCHLORIDE tablet, film coated. FDA-approved drug product labeling, 07 2009. Last accessed on DailyMed 05/15/2010.Google Scholar
- Mylan. cimetidine (Cimetidine) tablet, film coated. FDA-approved drug product labeling, 07 2007. Last accessed on DailyMed 12/28/2009.Google Scholar
- S. H. Preskorn. How drug-drug interactions can impact managed care. The American Journal of Managed Care, 10(6 Suppl): S186--S198, July 2004.Google Scholar
- Teva. trimethoprim (Trimethoprim) tablet. FDA-approved drug product labeling, 06 2008. Last accessed on DailyMed 05/22/2010.Google Scholar
- Teva Pharmaceuticals. fluconazole (fluconazole) Teva. FDA-approved drug product labeling, 10 2006. Last accessed on DailyMed 05/22/2010.Google Scholar
- Watson. mexiletine hcl (Mexiletine hydrochloride) capsule. FDA-approved drug product labeling, 04 2008. Last accessed on DailyMed 05/22/2010.Google Scholar
- D. S. Wishart, C. Knox, A. C. Guo, S. Shrivastava, M. Hassanali, P. Stothard, Z. Chang, and J. Woolsey. Drugbank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res, 34(Database issue): D668--D672, 2006.Google Scholar
- R. Yuan, T. Parmelee, J. D. Balian, R. S. Uppoor, F. Ajayi, A. Burnett, L. J. Lesko, and P. Marroum. In vitro metabolic interaction studies: experience of the Food and Drug Administration. Clin Pharmacol Ther, 66(1):9--15, 1999.Google ScholarCross Ref
Index Terms
- Leveraging the semantic web and natural language processing to enhance drug-mechanism knowledge in drug product labels
Recommendations
Drug Repurposing: Targeting mTOR Inhibitors for Anticancer Activity
CSBio '17: Proceedings of the 8th International Conference on Computational Systems-Biology and BioinformaticsIn the search of safer and more effective drugs while reducing costs and increasing productivity of novel drug discovery, scientists are changing their focus to an approach known as drug repurposing. This involves finding a new therapeutic effect of an ...
Potential drug-drug interactions in pediatric outpatient prescriptions for newborns and infants
ObjectivesTo surveyed the quantities, types, and related information of potential drug-drug interactions (DDIs) and estimate the off-label use percentage of pediatric outpatient prescriptions for newborns and infants from the National Health Insurance ...
Physicians' responses to computerized drug-drug interaction alerts for outpatients
IntroductionAdverse drug reactions (ADR) increase morbidity and mortality; potential drug-drug interactions (DDI) increase the probability of ADR. Studies have proven that computerized drug-interaction alert systems (DIAS) might reduce medication errors ...
Comments